Advances in Pulmonary Hypertension,
Год журнала:
2023,
Номер
22(3), С. 1 - 32
Опубликована: Ноя. 1, 2023
Pulmonary
hypertension
(PH)
is
characterized
by
increased
right
ventricular
(RV
)
afterload,
which
accommodated
early
dramatic
increases
in
RV
contractility
to
maintain
ventriculoarterial
coupling.Related
its
tissue
biology,
characteristics
of
differ
from
those
the
left
ventricle
(LV
).As
undergoes
adaptation
PH,
echocardiographic
signs
emerge
can
help
identify
PH
and
be
reassessed
noninvasively
prognosticate
outcomes
PH.Many
these
indices
calculated
standard
views
without
significant
modification
scanning
procedures.This
review
will
discuss
contemporary
diagnosis
highlighting
role
echocardiography
this
process.We
describe
differences
between
LV
RV,
including
adaptations
how
factors
impact
assessment.We
conclude
with
a
discussion
specific
parameters
their
reassessment.Routine
assessment
heart
improves
noninvasive
risk
stratification
may
reduce
delays
diagnosis,
ultimately
potentially
modifiable
disease
burden
patient
population.
European Journal of Clinical Investigation,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 28, 2025
Abstract
Pulmonary
hypertension
associated
with
left
heart
disease
(PH‐LHD)
represents
the
hemodynamic
condition
at
rest
resulting
from
pathologies
that
affect
ventricle
and/or
atrium.
Among
diseases,
failure
is
most
frequent
cause
of
PH.
PH‐LHD
common
PH,
accounting
for
65–80%
diagnoses.
Several
drugs
targeting
specific
signalling
pathways
involved
in
pulmonary
remodelling
PH‐LHD,
including
nitric
oxide,
MAP
kinase
and
endothelin‐1,
have
been
tested
randomized
clinical
trials
(RCTs),
disappointing
results
terms
efficacy
safety.
Therefore,
still
remains
orphan
therapies
able
to
counteract
pre‐
post‐capillary
circulation.
In
this
article,
we
will
discuss
pathophysiology
molecular
mechanisms
PH‐LHD.
We
focus
on
emerging
could
suggest
novel
targets
treatment
condition.
Postgraduate Medical Journal,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 31, 2025
Abstract
This
paper
provides
a
comprehensive
overview
of
cardiopulmonary
events
associated
with
the
occurrence,
development,
and
treatment
tumours,
serving
as
valuable
resource
for
clinical
management
cancer
patients.
It
explores
complex
relationship
between
heart
lungs,
collectively
discussing
implications
linked
to
tumours.
Common
risk
factors
that
connect
tumours
cardiac
pulmonary
conditions
are
delineated,
highlighting
their
direct
indirect
correlations.
Additionally,
addresses
disorders
symptoms
resulting
from
tumour
progression
subsequent
manifestations.
The
final
section
focuses
on
repercussions
various
treatments,
including
chemotherapy,
targeted
therapy,
radiation
immunotherapy,
elaborating
effects.
Effective
aggressive
proliferative
diseases,
such
requires
selecting
appropriate
modalities
balance
therapeutic
efficacy
vigilant
monitoring
function
thorough
assessment
outcomes
related
side
Cardiology in Review,
Год журнала:
2025,
Номер
unknown
Опубликована: Июнь 4, 2025
Mirabegron,
a
selective
β3-adrenergic
receptor
agonist
approved
for
overactive
bladder,
is
being
investigated
its
cardiovascular
applications,
particularly
in
heart
failure
(HF)
and
left
ventricular
hypertrophy.
This
review
explores
the
mechanistic
rationale,
safety
profile,
emerging
clinical
data
supporting
stimulation
as
novel
therapeutic
strategy.
Unlike
β1-blockers,
mirabegron
activates
nitric
oxide-dependent
pathways
that
confer
vasodilatory,
antifibrotic,
autonomic
regulatory
benefits,
relevant
HF
with
preserved
ejection
fraction.
However,
use
raises
concerns,
including
modest
increases
blood
pressure,
rate,
QTc
interval,
especially
high-risk
cardiac
populations.
Early
trials
have
shown
improvements
hemodynamic
parameters
such
index
pulmonary
vascular
resistance,
neutral
or
favorable
impact
on
symptoms
function.
Nevertheless,
long-term
safety,
optimal
patient
selection,
potential
combination
therapy
established
treatments
remain
unresolved.
Future
research
must
prioritize
identifying
biomarkers
predictive
of
response,
evaluating
synergy
current
therapies,
determining
durability
benefits.
Mirabegron
represents
promising,
mechanistically
distinct
approach
to
neurohormonal
modulation
HF,
address
gaps
unmet
by
conventional
therapies.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(12), С. 9971 - 9971
Опубликована: Июнь 9, 2023
Pulmonary
hypertension
(PH)
associated
with
left
heart
diseases
(PH-LHD),
also
termed
group
2
PH,
represents
the
most
common
form
of
PH.
It
develops
through
passive
backward
transmission
elevated
pressures
in
setting
failure,
either
preserved
(HFpEF)
or
reduced
(HFrEF)
ejection
fraction,
which
increases
pulsatile
afterload
right
ventricle
(RV)
by
reducing
pulmonary
artery
(PA)
compliance.
In
a
subset
patients,
progressive
remodeling
circulation
resulted
pre-capillary
phenotype
vascular
resistance
(PVR)
further
increasing
RV
afterload,
eventually
leading
to
RV-PA
uncoupling
and
failure.
The
primary
therapeutic
objective
PH-LHD
is
reduce
left-sided
appropriate
use
diuretics
guideline-directed
medical
therapies
for
When
established,
targeted
aiming
PVR
are
theoretically
appealing.
So
far,
such
have
mostly
failed
show
significant
positive
effects
patients
PH-LHD,
contrast
their
proven
efficacy
other
forms
Whether
may
benefit
some
specific
subgroups
(HFrEF,
HFpEF)
hemodynamic
phenotypes
(post-
PH)
various
degrees
dysfunction
still
needs
be
addressed.
Biomedicines,
Год журнала:
2024,
Номер
12(9), С. 1936 - 1936
Опубликована: Авг. 23, 2024
Pulmonary
Embolism
(PE)
is
a
life-threatening
condition
initiated
by
the
presence
of
blood
clots
in
pulmonary
arteries,
leading
to
severe
morbidity
and
mortality.
Underlying
mechanisms
involve
endothelial
dysfunction,
including
impaired
flow
regulation,
pro-thrombotic
state,
inflammation,
heightened
oxidative
stress,
altered
vascular
remodeling.
These
contribute
diseases
stemming
from
PE,
such
as
recurrent
thromboembolism,
chronic
thromboembolic
hypertension,
post-thrombotic
syndrome,
right
heart
failure,
cardiogenic
shock.
Detailing
key
risk
factors
utilizing
hemodynamic
stability-based
categorization,
review
aims
for
precise
stratification
applying
established
diagnostic
tools
scoring
systems.
This
article
explores
both
conventional
emerging
biomarkers
potential
tools.
Additionally,
synthesizing
existing
knowledge,
it
provides
comprehensive
outlook
current
enhanced
PE
management
preventive
strategies.
The
conclusion
underscores
need
future
research
improve
accuracy
therapeutic
effectiveness
PE.
ESC Heart Failure,
Год журнала:
2023,
Номер
10(6), С. 3582 - 3591
Опубликована: Сен. 29, 2023
Patients
with
heart
failure
(HF)
exhibit
poor
prognosis,
which
is
further
deteriorated
by
pulmonary
hypertension
(PH),
negative
impact
on
morbidity
and
mortality.
As
PH
due
to
left
HF
(LHF-PH)
among
the
most
common
causes
of
PH,
there
an
urge
according
2021
European
Society
Cardiology
guidelines
find
new
biomarkers
that
aid
in
prognostication
this
patient
cohort.
Given
role
tumour
necrosis
factor-alpha
(TNF-α)
progression,
we
aimed
investigate
prognostic
value
plasma
proteins
related
TNF-α
patients
LHF-PH,
relation
haemodynamic
changes
following
transplantation
(HT).
Advances in Pulmonary Hypertension,
Год журнала:
2023,
Номер
22(3), С. 134 - 139
Опубликована: Ноя. 1, 2023
Pulmonary
hypertension
(PH)
from
left-sided
heart
disease
(group-II
PH)
is
an
increasingly
recognized
cause
of
PH
in
pediatrics.
Group-II
can
result
obstruction
at
any
level
the
left
heart,
and
progress
over
time.
Management
be
particularly
difficult,
as
targeted
therapy
setting
a
fixed
carries
risk
pulmonary
vascular
congestion
edema.
Based
on
existing
evidence,
use
vasodilators
group
II
not
recommended,
management
centers
around
early
identification
correction
underlying
lesion.
In
this
review,
we
highlight
pathophysiology
group-II
PH,
diagnostic
evaluation
pathology,
general
approach
to
both
medical
surgical
management,
with
particular
attention
relevant
lesions.
multifaceted
progressive
process
that
poses
difficult
challenge
clinicians,
requires
thoughtful
individualized
management.
ESC Heart Failure,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 11, 2024
Abstract
Heart
failure
(HF),
the
final
manifestation
of
most
cardiovascular
diseases,
has
become
a
major
global
health
concern,
affecting
millions
individuals.
Despite
basic
drug
treatments,
patients
present
with
high
morbidity
and
mortality
rates.
However,
recent
advancements
in
interventional
therapy
have
shown
promising
results
improving
prognosis
HF.
These
include
transcatheter
aortic
valve
replacement
for
severe
stenosis,
mitral
repair
chronic
regurgitation,
neuromodulation
multiple
targets
measures
treatment
HF
left
ventricular
assist
device
implantation
advanced
(
Figure
1
).
In
this
review,
we
aimed
to
provide
an
overview
current
progress
therapies
